Fiasp Flex Touch 100100 IU/ml

Fiasp Flex Touch 100 is a rapid-acting human insulin analog indicated for the treatment of diabetes mellitus to improve glycemic control.

Established / FDA-approved uses

• Type 1 diabetes mellitus in adults and pediatric patients, as part of an insulin regimen that includes a longer-acting (basal) insulin.
• Type 2 diabetes mellitus in adults, used alone or in combination with oral antidiabetic agents or basal insulin, when mealtime (prandial) glycemic control is needed.

Route of use

• Subcutaneous injection shortly before a meal (mealtime/bolus insulin).
• Continuous subcutaneous insulin infusion (CSII) via an insulin pump.
• Certain formulations of Fiasp Flex Touch 100 are approved for intravenous administration under close medical supervision (e.g., in hospital settings for diabetic ketoacidosis or perioperative glycemic control), and for ultra-rapid subcutaneous use immediately before or shortly after starting a meal.

Fiasp Flex Touch 100 is not a substitute for basal insulin and does not treat diabetic ketoacidosis on its own; it is used as part of a comprehensive diabetes management plan under medical supervision.

Each mL of injectable solution contains Insulin Aspart (rDNA origin) 100 units, along with excipients such as glycerol, phenol, metacresol, zinc chloride, sodium chloride, disodium hydrogen phosphate dihydrate, and water for injection, with pH adjusted using hydrochloric acid/sodium hydroxide as needed.

Fiasp Flex Touch 100 is a rapid-acting, recombinant human insulin analog produced by recombinant DNA technology using Saccharomyces cerevisiae. It differs from regular human insulin by a single amino acid substitution (proline replaced by aspartic acid at position B28), which reduces self-association of insulin molecules, allowing faster absorption after subcutaneous injection compared with regular human insulin.

Fiasp Flex Touch 100 has an onset of action of approximately 10–20 minutes, peak effect at 1–3 hours, and a duration of action of approximately 3–5 hours, making it suitable for mealtime (prandial) glucose control.

Fiasp Flex Touch 100 belongs to the therapeutic class of rapid-acting insulin analogs, a subclass of antidiabetic agents used for glycemic control in diabetes mellitus.

The primary action of Insulin Aspart is regulation of glucose metabolism. Insulins, including Insulin Aspart, lower blood glucose by binding to insulin receptors on target tissues (skeletal muscle and fat), stimulating peripheral glucose uptake, and inhibiting hepatic glucose production. Insulin also inhibits lipolysis and proteolysis while enhancing protein synthesis.

Insulin Aspart has a more rapid onset and shorter duration of action than regular human insulin because the B28 amino acid substitution reduces molecular self-association, promoting faster dissociation into monomers and faster absorption from the subcutaneous injection site.

• Administer Fiasp Flex Touch 100 by subcutaneous injection into the abdomen, thigh, buttock, or upper arm, rotating injection sites to reduce the risk of lipodystrophy.
• May also be given by continuous subcutaneous infusion using an insulin pump, or, for select formulations under medical supervision, by intravenous infusion in a monitored clinical setting.
• Do not administer intramuscularly or dilute/mix with other insulins unless specifically directed by a physician, as this can alter the absorption profile.
• Visually inspect the solution before use; it should be clear and colorless. Do not use if it appears cloudy, discolored, or contains particles.
• Do not share Fiasp Flex Touch 100 pens, cartridges, or syringes between patients, even if the needle is changed.

Several medicines can affect blood glucose requirements when taken with Fiasp Flex Touch 100, requiring dose adjustment and closer monitoring:

• Drugs that may increase the risk of hypoglycemia: oral antidiabetic agents, ACE inhibitors, angiotensin receptor blockers, disopyramide, fibrates, fluoxetine, monoamine oxidase inhibitors, pentoxifylline, propoxyphene, salicylates, somatostatin analogs (e.g., octreotide), and sulfonamide antibiotics.
• Drugs that may decrease the glucose-lowering effect (risk of hyperglycemia): corticosteroids, danazol, diuretics, sympathomimetic agents (e.g., epinephrine, albuterol, terbutaline), isoniazid, niacin, oral contraceptives, phenothiazines, atypical antipsychotics, protease inhibitors, somatropin, and thyroid hormones.
• Beta-blockers, clonidine, guanethidine, and reserpine may blunt or mask the signs and symptoms of hypoglycemia, delaying recognition and treatment.
• Alcohol may potentiate or reduce the glucose-lowering effect of Fiasp Flex Touch 100 unpredictably.

Inform the physician of all concurrent medications before starting Fiasp Flex Touch 100.

The most common and clinically important adverse effect of Fiasp Flex Touch 100 is hypoglycemia, which can be serious and, in severe cases, life-threatening. Symptoms include sweating, tremor, palpitations, confusion, blurred vision, and, if untreated, seizures or loss of consciousness.

Other reported side effects include:

• Injection site reactions: redness, swelling, itching, or pain at the injection site.
• Lipodystrophy (lipohypertrophy or lipoatrophy) at repeated injection sites.
• Weight gain.
• Peripheral edema, particularly when starting insulin therapy or intensifying glucose control.
• Allergic reactions, ranging from mild local reactions to rare systemic hypersensitivity/anaphylaxis.
• Hypokalemia (low blood potassium) with insulin therapy in general.

Fiasp Flex Touch 100 may be used during pregnancy when clinically indicated for glycemic control, as poorly controlled diabetes in pregnancy carries risks to both mother and fetus; however, it should be used only under close medical supervision, with the physician weighing potential benefits against potential risks. Insulin requirements often change during pregnancy and the postpartum period, requiring closer glucose monitoring and dose adjustment.

During breastfeeding, insulin, including Fiasp Flex Touch 100, is generally considered compatible as it is a naturally occurring hormone that does not appear to pass into breast milk in a manner that harms the infant; however, maternal insulin dose and diet may need adjustment during lactation. Use only under medical advice and supervision.

Hypoglycemia: the most common risk with Fiasp Flex Touch 100; patients and caregivers should be educated to recognize and promptly treat low blood sugar. Risk is increased by changes in meal pattern, exercise, illness, alcohol use, or concomitant medications (see Interactions).

Hyperglycemia and ketoacidosis with insulin pump use: interruption of insulin delivery (e.g., pump malfunction, infusion set blockage) can rapidly lead to hyperglycemia and diabetic ketoacidosis; patients using pumps must monitor glucose closely and have a backup insulin delivery method.

Do not interchange Fiasp Flex Touch 100 with other insulin products (different brands, types, or concentrations) without explicit medical guidance, as this can cause dosing errors resulting in severe hypoglycemia or hyperglycemia.

Hypokalemia: all insulins, including Fiasp Flex Touch 100, can cause a shift of potassium into cells, leading to hypokalemia, which may cause cardiac arrhythmias; monitor potassium in at-risk patients (e.g., those on potassium-lowering drugs or with renal impairment).

Hypersensitivity reactions: discontinue Fiasp Flex Touch 100 and seek immediate medical attention if signs of severe allergic reaction (generalized rash, angioedema, dyspnea, hypotension) occur.

Renal and hepatic impairment: may alter insulin clearance and requirements; monitor glucose more frequently and adjust dose accordingly.

Beta-blockers and other masking agents: can reduce the warning signs of hypoglycemia (see Interactions); use with caution and increased glucose monitoring.

Lipodystrophy: rotate injection sites within the same body region to reduce the risk of lipodystrophy, which can affect insulin absorption.

Any change in insulin regimen, including a switch to or from Fiasp Flex Touch 100, should be made cautiously and only under medical supervision.

Overdose of Fiasp Flex Touch 100 relative to food intake, physical activity, or concomitant glucose-lowering agents can result in severe hypoglycemia, which may present as confusion, seizures, loss of consciousness, or (rarely) death if not treated promptly.

Mild hypoglycemia can often be managed by immediate intake of fast-acting oral glucose or sugar-containing food. Severe hypoglycemia with impaired consciousness requires immediate medical attention or emergency services, and may need treatment with glucagon injection or intravenous glucose administered by a trained caregiver or healthcare professional. Contact a physician, emergency services, or a poison control center immediately in any case of suspected significant overdose.

Store unopened Fiasp Flex Touch 100 vials, cartridges, or pens in a refrigerator (2°C to 8°C); do not freeze, and discard if it has been frozen. Once in use (opened), Fiasp Flex Touch 100 may generally be kept at room temperature (below 30°C), away from direct heat and light, and used within the period specified on the product labeling (commonly up to 28 days), after which any remaining medicine should be discarded. Keep out of reach of children. Always check the manufacturer's specific storage instructions on the pack.

Renal impairment: insulin requirements may be reduced due to decreased insulin clearance; monitor blood glucose closely and adjust the dose of Fiasp Flex Touch 100 as needed.

Hepatic impairment: insulin requirements may be reduced due to decreased gluconeogenesis and insulin metabolism; monitor glucose closely.

Elderly patients: use with caution; start with conservative dosing and titrate carefully, as elderly patients may have increased sensitivity to hypoglycemia and reduced ability to recognize warning symptoms.

Pediatric patients: Fiasp Flex Touch 100 is approved for use in children with diabetes mellitus from the ages specified in the product labeling (commonly 2 years and above for injection, and select formulations for pump use); dosing must be individualized by a pediatric specialist.

Pregnancy and lactation: see the Pregnancy and Lactation section.

Diabetes mellitus is a chronic condition, and Fiasp Flex Touch 100 is typically used long-term as part of ongoing glycemic management. Duration of treatment is determined by the treating physician based on the type of diabetes, response to therapy, and overall treatment plan; it is not intended for short-term or as-needed use except as specifically directed (e.g., correction doses, hospital glucose management).

Insulin Aspart is classified under: Antidiabetic agents > Insulins > Rapid-acting insulin analogs.

Insulin Aspart binds to insulin receptors on muscle and adipose tissue, activating downstream signaling that promotes glucose transporter (GLUT4) translocation to the cell membrane, thereby increasing cellular glucose uptake. Simultaneously, it suppresses hepatic glucose output by inhibiting gluconeogenesis and glycogenolysis, inhibits lipolysis in adipocytes, and inhibits proteolysis while stimulating protein synthesis. The amino acid substitution at position B28 in Insulin Aspart reduces self-association into hexamers, allowing faster dissociation into active monomers/dimers after subcutaneous injection and thus a more rapid onset of glucose-lowering action compared with regular human insulin.

Category B

Fiasp Flex Touch 100 is approved for the treatment of diabetes mellitus in pediatric patients from the age specified in the applicable product labeling (commonly from 2 years of age for subcutaneous injection, and from the age specified by the manufacturer for insulin pump use). Safety and efficacy of specific formulations or delivery methods below the labeled age have not been established, and use in very young children should be undertaken only under the close supervision of a pediatric endocrinologist, with careful attention to dosing accuracy, hypoglycemia recognition, and glucose monitoring, given children's variable dietary intake and activity levels.